Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
November 06, 2023 07:00 ET
|
Instil Bio
DALLAS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies...
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023 07:00 ET
|
Instil Bio
ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical trial anticipated in 2024 ITIL-306 operational...
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
June 26, 2023 16:38 ET
|
Instil Bio
Presented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors ITIL-306, first CoStAR-TIL in clinical development,...
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023 07:00 ET
|
Instil Bio
ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H’2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 Cash runway beyond 2026 DALLAS, May 11,...
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 31, 2023 07:00 ET
|
Instil Bio
Instil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 ...
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
January 31, 2023 17:00 ET
|
Instil Bio
Company anticipates cash resources to provide runway beyond 2026 Initial clinical data from the ITIL-306 program expected in 2023 Instil is consolidating manufacturing and Phase 1 clinical trial of...
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
January 09, 2023 07:00 ET
|
Instil Bio
Phase 1 trial of ITIL-306 in NSCLC, ovarian, and RCC re-opened to enrollment after voluntary pause Initial data readout for ITIL-306 expected in 2023 With recent reprioritization of clinical...
Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce
December 08, 2022 07:00 ET
|
Instil Bio
Discontinuing unmodified TIL programs, including DELTA-1 and DELTA-2 trials of ITIL-168Prioritizing CoStAR-TIL programs for clinical development, including ITIL-306 in Phase 1 trial for NSCLC,...
Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022 16:07 ET
|
Instil Bio
Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1’23 Reprioritization of resources with enrollment deferred in DELTA-2 trial of ITIL-168 First...
Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 08, 2022 07:00 ET
|
Instil Bio
DALLAS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies...